On December 2, 2022 Privo Technologies, Inc. reported that it has received IRB approval for its CLN-004 study from WCG IRB (Press release, Privo Technologies, DEC 2, 2022, View Source;utm_medium=rss&utm_campaign=privo-technologies-inc-receives-irb-approval-for-prv211-intraoperative-chemotherapy-treatment-for-solid-tumors-s-2-2-2 [SID1234624746]). CLN-004 is a Phase 1/2, open-label, safety and efficacy study accessing the tolerability, anti-tumor effects, systemic exposure, and device technical effects of PRV211 (Cisplatin Intraoperative System) in Subjects with T2-T3 Oral Squamous Cell Carcinoma (OSCC) amenable to surgery. PRV211 is a sterilized derivative of the nano engineered PRV platform intended for intraoperative chemotherapy treatment for all solid tumor surgeries immediately following surgical excision. The goal is to treat the tumor bed locally, eliminating any remaining micro metastases or close margins that are unable to be fully resected while avoiding system circulation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is Privo’s 3rd IRB approval with WCG.

The WCG IRB, formally known as the WIRB Copernicus Group, Inc., is the industry leader in ethical review of clinical trial protocols with over 50 years of experience.